Come si colloca il rapporto MBRX di PB rispetto ai suoi colleghi?

MBRX is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (0.8x).

Come si colloca il MBRX's PB Ratio rispetto ad altre aziende del US Biotechs settore?

MBRX is good value based on its Price-To-Book Ratio (0.4x) compared to the US Biotechs industry average (1.8x).

Qual è il MBRX PB Ratio rispetto al suo Fair PB Ratio? Si tratta del PB Ratio atteso, tenendo conto delle previsioni di crescita degli utili, dei margini di profitto e di altri fattori di rischio della società.

Insufficient data to calculate MBRX's Price-To-Book Fair Ratio for valuation analysis.

Qual è il prezzo equo di MBRX se si considerano i suoi flussi di cassa futuri? Per questa stima utilizziamo un modello di Discounted Cash Flow.

Insufficient data to calculate MBRX's fair value for valuation analysis.

Qual è la previsione a 12 mesi degli analisti e abbiamo una qualche fiducia statistica nell'obiettivo di prezzo del consenso?

Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine [[statistical confidence]] in agreement.

Moleculin Biotech (Nasdaq:MBRX) - Prezzo delle azioni, notizie e analisi

MBRX Panoramica delle azioni

Moleculin Biotech, Inc. è un'azienda farmaceutica in fase clinica che si concentra sullo sviluppo di candidati farmaci per il trattamento di tumori e virus.

Informazioni sull'azienda

MBRX analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Analisi del rischio

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($7M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

+ 1 più rischio

Moleculin Biotech, Inc. Concorrenti

Eagle Pharmaceuticals

OTCPK:EGRX

US$7.1m

Organovo Holdings

NasdaqCM:ONVO

US$7.1m

GT Biopharma

NasdaqCM:GTBP

US$6.6m

Cyclerion Therapeutics

NasdaqCM:CYCN

US$7.4m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Moleculin Biotech
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$2.45
Massimo di 52 settimane	US$15.75
Minimo di 52 settimane	US$2.12
Beta	1.86
1Variazione di 1 mese	3.81%
Variazione a 3 mesi	11.36%
Variazione di 1 anno	-72.20%
3Variazione a 3 anni	-93.54%
Variazione a 5 anni	-97.43%
Variazione dall'IPO	-99.66%

Notizie e aggiornamenti recenti

Recent updates

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Dec 20

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Jul 14

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Feb 18

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Nov 01

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Sep 27

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Sep 06

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jul 11

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Jul 08

Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jan 15

Moleculin Bio's Annamycin an Orphan Drug in U.S. for soft tissue sarcomas

Dec 29

Rendimenti per gli azionisti

	MBRX	US Biotechs	US Mercato
7D	-6.5%	-0.7%	-1.6%
1Y	-72.2%	19.8%	30.8%

Ritorno vs Industria: MBRX underperformed the US Biotechs industry which returned 19.8% over the past year.

Rendimento vs Mercato: MBRX underperformed the US Market which returned 30.8% over the past year.

Volatilità dei prezzi

Is MBRX's price volatile compared to industry and market?
MBRX volatility
MBRX Average Weekly Movement	11.0%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Prezzo delle azioni stabile: MBRX's share price has been volatile over the past 3 months compared to the US market.

Volatilità nel tempo: MBRX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2015	18	Wally Klemp	moleculin.com

Moleculin Biotech, Inc. è un'azienda farmaceutica in fase clinica che si concentra sullo sviluppo di candidati farmaci per il trattamento di tumori e virus. Il suo principale candidato è l'Annamicina, in fase di sperimentazione clinica di Fase 1B/2 per il trattamento della leucemia mieloide acuta (AML) recidivata o refrattaria e del sarcoma dei tessuti molli metastatizzato ai polmoni. L'azienda sta inoltre sviluppando WP1066, un modulatore immuno-trascrizionale progettato per inibire la trasduzione fosforilata del segnale e l'attivatore della trascrizione e altri fattori di trascrizione oncogeni, mirati al trattamento dei tumori cerebrali, del pancreas e di altri tipi di cancro.

Moleculin Biotech, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Moleculin Biotech con la sua capitalizzazione di mercato?
MBRX statistiche fondamentali
Capitalizzazione di mercato	US$6.97m
Guadagni(TTM)	-US$25.17m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.3x

Rapporto P/E

MBRX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
MBRX Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$25.17m
Guadagni	-US$25.17m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-8.85
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato MBRX nel lungo periodo?

Vedi performance storica e confronto

MBRX Panoramica delle azioni

Premi

Analisi del rischio

Moleculin Biotech, Inc. Concorrenti

OTCPK:EGRX

US$7.1m

NasdaqCM:ONVO

US$7.1m

NasdaqCM:GTBP

US$6.6m

NasdaqCM:CYCN

US$7.4m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

New major risk - Share price stability

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

New major risk - Shareholder dilution

Moleculin Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $5.497817 million.

Moleculin Biotech, Inc. Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering.

Recent updates

New major risk - Share price stability

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

New major risk - Shareholder dilution

Moleculin Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $5.497817 million.

Moleculin Biotech, Inc. Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering.

Moleculin Biotech, Inc. Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

New major risk - Market cap size

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)

Moleculin Biotech, Inc. to Report Q1, 2024 Results on May 10, 2024

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman

New major risk - Market cap size

Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

New major risk - Financial position

New major risk - Share price stability

Moleculin Biotech, Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

Moleculin Biotech, Inc. Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Moleculin Biotech, Inc. announced that it expects to receive $9.01739 million in funding

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

New major risk - Financial position

Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

Moleculin Biotech, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Moleculin Biotech Receives an Extension of the 180 Calendar Days from Nasdaq to Regain Compliance with the Bid Price Requirement

New major risk - Share price stability

Moleculin Biotech, Inc. Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

New major risk - Financial position

Moleculin Biotech, Inc. Provides Update on Ongoing Clinical Trials

Moleculin Biotech, Inc. to Report Q2, 2023 Results on Aug 11, 2023

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Moleculin Biotech, Inc., Annual General Meeting, Jun 15, 2023

Moleculin Biotech Receives Non-Compliance Notice From Nasdaq

Moleculin Biotech, Inc. to Report Q1, 2023 Results on May 11, 2023

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Moleculin Biotech, Inc. Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Founder recently bought US$58k worth of stock

Founder recently bought US$108k worth of stock

Price target decreased to US$8.67

Moleculin Biotech, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech, Inc Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech, Inc. Announces WP1096 Molecule Will Be Evaluated in Animal Studies Through the Preclinical Services Offered by the National Institute of Allergy and Infectious Diseases

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Moleculin Biotech, Inc. Announces Completion of Third Single Ascending Dose Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Price target decreased to US$11.67

Price target increased to US$21.50

Moleculin Concludes Phase 1B and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech, Inc. Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Moleculin Biotech, Inc. Announces Completion of First Single Ascending Dose (Sad) Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)